Prospects for e+e- physics at Frascati between the phi and the psi

We present a detailed study, done in the framework of the INFN 2006 Roadmap, of the prospects for e+e- physics at the Frascati National Laboratories. The physics case for an e+e- collider running at high luminosity at the phi resonance energy and also reaching a maximum center of mass energy of 2.5 GeV is discussed, together with the specific aspects of a very high luminosity tau-charm factory. Subjects connected to Kaon decay physics are not discussed here, being part of another INFN Roadmap working group. The significance of the project and the impact on INFN are also discussed. All the documentation related to the activities of the working group can be found in http://www.roma1.infn.it/people/bini/roadmap.html.Comment: INFN Roadmap Report: 86 pages, 25 figures, 9 table

The characterization of fluorinated graphite

The characterization of solid fossil fuels by chemical and spectroscopic methods requires extensive modelling in less complex systems for chemical proof of principle and technique development. In previous work coal was fluorinated with dilute, elemental fluorine under conditions that were expected to lead to materials that contain only fluoromethine moieties. The solid state, cross polarization/magic angle spinning (CP/MAS) {sup 13}C NMR spectra of the fluorinated coal are complex, indicating more chemical modification than originally anticipated. Our goal in the coal derivatization was to sequentially increase the severity of the fluorination and observe by {sup 19}F and {sup 13}C NMR the type and concentration of fluorine functional groups created in the coal milieu. This requires the ability to discriminate between C, CF, CF{sub 2}, and CF, moieties in the coal matrix. The task can be accomplished by implementing the spectral editing technique of Wu and Zilm which distinguishes different kinds of carbon resonances, especially CH and CH{sub 2} resonances. These experiments utilize cross polarization (CP) and polarization inversion (PI) to effect the discrimination. Our version of this experiment is a triple resonance experiment that incorporates {sup 19}F-{sup 13}C CP, PI, and simultaneous {sup 1}H and {sup 19}F dipolar decoupling. In order to evaluate the elemental fluorine chemistry in a matrix simpler than coal, fluorinated graphite was prepared. X-ray photoelectron spectroscopy (XPS) was used to characterize the surface species, i.e., count CF, CF{sub 2} and CF{sub 3} species. These well-characterized samples are the models we will use to test the NIVIR editing experiments. The XPS and atomic force microscopy (AFM) data on the first fluorinated graphites we have prepared are reported in this paper

Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype

We discovered a new chemical class of antiproliferative agents, 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides. SAR-guided optimization of the two distinct terminal fragments yielded a compound with 120 nM potency in an antiproliferative assay. Biological activity profile studies (COMPARE analysis) demonstrated that 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides act as tubulin inhibitors, and this conclusion was confirmed via biochemical assays with pure tubulin and demonstration of increased numbers of mitotic cells following treatment of a leukemia cell line. © 2014 Elsevier Ltd. All rights reserved

Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype

We discovered a new chemical class of antiproliferative agents, 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides. SAR-guided optimization of the two distinct terminal fragments yielded a compound with 120 nM potency in an antiproliferative assay. Biological activity profile studies (COMPARE analysis) demonstrated that 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides act as tubulin inhibitors, and this conclusion was confirmed via biochemical assays with pure tubulin and demonstration of increased numbers of mitotic cells following treatment of a leukemia cell line. © 2014 Elsevier Ltd. All rights reserved